Humasis Co. Ltd Asset Resilience Ratio

Latest as of September 2025: 52.35%

Humasis Co. Ltd asset resilience ratio. Humasis Co. Ltd (205470) has an Asset Resilience Ratio of 52.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Humasis Co. Ltd (205470) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩177.84 Billion
≈ $120.52 Million USD Cash + Short-term Investments

Total Assets

₩339.69 Billion
≈ $230.21 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Humasis Co. Ltd (2016–2024)

Asset resilience ratio of Humasis Co. Ltd from 2016 to 2024. This chart shows how Humasis Co. Ltd's Asset Resilience Ratio has changed over time. Read 205470 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Humasis Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Humasis Co. Ltd asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩177.84 Billion 52.35%
Total Liquid Assets ₩177.84 Billion 52.35%

Asset Resilience Insights

  • Very High Liquidity: Humasis Co. Ltd maintains exceptional liquid asset reserves at 52.35% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Humasis Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Humasis Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
BMC Medical Co. Ltd. A
SHE:301367
Medical Devices 44.96%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Hironic Co. Ltd
KQ:149980
Medical Devices 17.42%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Adherium Ltd
AU:ADR
Medical Devices 15.45%

Humasis Co. Ltd Asset Resilience Ratio by Year (2016–2024)

Humasis Co. Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Humasis Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 58.65% ₩194.68 Billion
≈ $131.93 Million
₩331.92 Billion
≈ $224.93 Million
-11.31pp
2023-12-31 69.96% ₩242.99 Billion
≈ $164.67 Million
₩347.31 Billion
≈ $235.37 Million
+1.80pp
2022-12-31 68.16% ₩318.69 Billion
≈ $215.97 Million
₩467.53 Billion
≈ $316.84 Million
+10.88pp
2021-12-31 57.29% ₩195.19 Billion
≈ $132.28 Million
₩340.71 Billion
≈ $230.90 Million
+23.65pp
2020-12-31 33.64% ₩22.99 Billion
≈ $15.58 Million
₩68.35 Billion
≈ $46.32 Million
-25.57pp
2019-12-31 59.21% ₩21.60 Billion
≈ $14.64 Million
₩36.49 Billion
≈ $24.73 Million
-1.64pp
2018-12-31 60.85% ₩20.87 Billion
≈ $14.14 Million
₩34.29 Billion
≈ $23.24 Million
+6.10pp
2017-12-31 54.75% ₩15.51 Billion
≈ $10.51 Million
₩28.32 Billion
≈ $19.19 Million
-45.03pp
2016-12-31 99.78% ₩12.10 Billion
≈ $8.20 Million
₩12.13 Billion
≈ $8.22 Million
--
pp = percentage points

About Humasis Co. Ltd

KQ:205470 Korea Medical Devices
Market Cap
$172.92 Million
₩255.16 Billion KRW
Market Cap Rank
#16906 Global
#646 in Korea
Share Price
₩2255.00
Change (1 day)
-2.80%
52-Week Range
₩682.00 - ₩4265.00
All Time High
₩8520.77
About

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more